What is Oxyrase?
Oxyrase operates at the intersection of microbiology and biotechnology, specializing in the development of advanced anaerobic culture media. Its flagship offerings, including the Oxyrase Enzyme System and OxyPlate, are engineered to facilitate the growth of oxygen-sensitive organisms by effectively removing oxygen from culture environments. This technology is essential for hospitals, clinical laboratories, and pharmaceutical research facilities that require precise, reliable conditions for microbial analysis and biological preservation.
With a legacy spanning over three decades, the company has transitioned from a niche provider to a foundational partner for institutions requiring high-integrity biological solutions. Their product suite not only simplifies complex anaerobic workflows but also provides robust antioxidant capabilities, ensuring the stability of sensitive materials throughout the research and diagnostic lifecycle.
How much funding has Oxyrase raised?
Oxyrase has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Oxyrase
PPP
Public-Private Partnership
What's next for Oxyrase?
Looking ahead, the strategic deployment of this capital will likely focus on expanding the reach of Oxyrase's proprietary enzyme systems into emerging global markets. As the demand for sophisticated diagnostic tools continues to rise, the company is well-positioned to enhance its research methodologies and broaden its portfolio of antioxidant solutions. By prioritizing operational efficiency and market penetration, Oxyrase aims to maintain its competitive edge in the anaerobic culture space, potentially exploring new applications in large-scale biological preservation and industrial biotech processes. This late-stage growth phase suggests a focus on sustainable scaling and the continued optimization of its core technological infrastructure.
See full Oxyrase company page
